Results 121 to 130 of about 20,057 (157)
Some of the next articles are maybe not open access.
Anesthesiology, 1964
In 1954 Beecher and Todd2 published an article in which they presented evidence that muscle relaxants increased mortality. This article and a few well‐placed speeches about the substance of the article precipitated a tremendous emotional reaction to the well‐established use of muscle relaxants.
openaire +2 more sources
In 1954 Beecher and Todd2 published an article in which they presented evidence that muscle relaxants increased mortality. This article and a few well‐placed speeches about the substance of the article precipitated a tremendous emotional reaction to the well‐established use of muscle relaxants.
openaire +2 more sources
Digestive Diseases, 1988
Hepatitis following halothane anaesthesia may take two forms: a mild self-limiting disease or a more severe hepatitis with a high mortality. Whether these two forms represent two distinct entities or ends of a spectrum is unclear. Severe hepatitis is commoner after multiple exposures and has many of the characteristics of an immune-mediated ...
J, Neuberger, R, Williams
openaire +2 more sources
Hepatitis following halothane anaesthesia may take two forms: a mild self-limiting disease or a more severe hepatitis with a high mortality. Whether these two forms represent two distinct entities or ends of a spectrum is unclear. Severe hepatitis is commoner after multiple exposures and has many of the characteristics of an immune-mediated ...
J, Neuberger, R, Williams
openaire +2 more sources
Survey of Anesthesiology, 1989
Halothane, an effective and usually safe anaesthetic agent, is rarely associated with the development of fulminant hepatic failure. Guidelines have been developed to reduce the probability of a patient developing halothane hepatitis. However, cases continue to occur and, in some cases, the guidelines have been ignored.
openaire +2 more sources
Halothane, an effective and usually safe anaesthetic agent, is rarely associated with the development of fulminant hepatic failure. Guidelines have been developed to reduce the probability of a patient developing halothane hepatitis. However, cases continue to occur and, in some cases, the guidelines have been ignored.
openaire +2 more sources
1978
Halothane (2-bromo-2-chloro-1:1:1-trifluoroethane) is a volatile, nonflammable anaesthetic agent which has been widely used for the last 20 years. Halothane hepatitis has been a matter of continuing controversy, but now it seems to be generally accepted as a clinical entity.
openaire +2 more sources
Halothane (2-bromo-2-chloro-1:1:1-trifluoroethane) is a volatile, nonflammable anaesthetic agent which has been widely used for the last 20 years. Halothane hepatitis has been a matter of continuing controversy, but now it seems to be generally accepted as a clinical entity.
openaire +2 more sources